Evaluate how trials can be run quicker using new biostatistical methods
Applied case study example of study design using the latest tools and methodologies
-
Phase-3 oncology design as a case study
-
Latest AI/ML tools to leverage Phase-2 study data to set patient inclusion/exclusion criterion for broadest possible label as well as increase probability of study success. This also potentially reduces cost and time to run trial
-
Use of latest adaptive trial design innovations to reduce trial cost, risk, and time
-
Adaptive accrual to incorporate actual response and hazard rates for efficient trial execution without sacrificing power
-
Case study wrap-up from clinician's perspective with all these efficiencies and optimizations
Join our upcoming webinar on October 25, and hear IQVIA’s VP Biostatistics Russ Reeve and AI/ML expert Kal Chaudhuri as they sets out to highlight how applied adaptive design using subgroup identification & machine learning can reduce trial risk, cost and runtime. Sign up now, and learn how to optimize your workflow using biostatistics and ML.
Register here https://globalmeet.webcasts.com/starthere.jsp?ei=1568893&tp_key=ed851ed0c6&sti=iqvia